来自官方财务报表的收入、利润与现金流历史。
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $105M | $39M | $47M | $79M | $47M | $73M | $34M | $3M | $0M |
| 毛利 | — | $39M | $47M | $79M | $47M | $73M | $34M | $2M | $0M |
| 毛利率% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 71.9% | — |
| 营业利润（EBIT） | ($351M) | ($349M) | ($262M) | ($166M) | ($161M) | ($101M) | ($46M) | ($42M) | ($21M) |
| 营业利润率% | -334.3% | -891.3% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% | — |
| 净利 | ($299M) | ($311M) | ($224M) | ($147M) | ($155M) | ($100M) | ($46M) | ($41M) | ($21M) |
| 净利润率 % | -284.8% | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1407.4% | — |
| EBITDA | — | ($303M) | ($216M) | ($143M) | ($152M) | ($98M) | ($44M) | ($40M) | ($21M) |
| 每股收益（EPS） | $-3.30 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.02 | $-0.93 | $-0.48 |
| 已发行股数 (M) | — | 84M | 75M | 58M | 54M | 48M | 45M | 45M | 45M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 KYMR 交互式查看器。 /companies/us/KYMR
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms